Fatty Liver Treatment Market Report 2026

Fatty Liver Treatment Market Overview

• Fatty Liver Treatment market size has reached to $25.05 billion in 2025 • Expected to grow to $35.67 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Increase In Alcohol Consumption • Market Trend: Pioneering Product Innovations To Transform The Market Landscape • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Fatty Liver Treatment Market?

Fatty liver disease is a condition in which fat builds up in the liver, causing various symptoms and complications. Fatty liver treatment refers to the multiple strategies, interventions, and actions to address and manage fatty liver disease. The main types of fatty liver treatment are anti-rejection drugs or immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, and anti-viral drugs. Anti-rejection drugs, also known as immunosuppressants, are a class of medications used to suppress or weaken the body's immune response. They are indicated for hepatitis, liver cancer, non-alcoholic fatty liver disease, and others and are used by hospitals, ambulatory surgery centers, and others.

What Is The Fatty Liver Treatment Market Growth Forecast?

The fatty liver treatment market size is expected to see strong growth in the next few years. It will grow to $35.67 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to development of novel NAFLD drugs, increased use of non-invasive diagnostics, growth in preventive healthcare, expansion of tele-hepatology services, rising investment in liver disease research. Major trends in the forecast period include rising prevalence of non-alcoholic fatty liver disease, increased focus on lifestyle-based treatment approaches, growing use of targeted drug therapies, expansion of early liver disease screening, integration of digital health for disease monitoring.

Global Fatty Liver Treatment Market Segmentation

1) By Treatment Type: Anti-Viral Drugs, Chemotherapy Drugs, Targeted Therapy, Anti-Fibrotic Drugs 2) By Disease Type: Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases 3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users Subsegments: 1) By Anti-Viral Drugs: Direct-Acting Antivirals (DAAs), Nucleos(t)ide Analogs 2) By Chemotherapy Drugs: Conventional Chemotherapy Agents, Novel Chemotherapeutics Under Investigation 3) By Targeted Therapy: Small Molecule Inhibitors, Monoclonal Antibodies 4) By Anti-Fibrotic Drugs: PPAR Agonists, FXR Agonists, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Other Insulin Sensitizers

What Is The Driver Of The Fatty Liver Treatment Market?

The increase in alcohol consumption is expected to propel the growth of the fatty liver treatment market going forward. Alcohol consumption refers to consuming beverages containing alcohol, a psychoactive substance with depressant effects on the central nervous system. Alcohol consumption can worsen fatty liver disease and lead to more severe liver conditions, including alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For instance, in November 2025, according to the OECD, a Paris-based intergovernmental organization, in 2023 per capita annual alcohol consumption across member countries averaged 8.5 liters of pure alcohol. Therefore, the increase in alcohol consumption is driving the growth of the fatty liver treatment industry.

Key Players In The Global Fatty Liver Treatment Market

Major companies operating in the fatty liver treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Intercept Pharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Genfit, Conatus Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Cardax Inc., Eisai Co. Ltd., Alnylam Pharmaceuticals Inc.

Global Fatty Liver Treatment Market Trends and Insights

Major companies operating in the fatty liver treatment market are focusing on developing innovative solutions, such as next-generation metabolic-modulating biologics, to meet the rising demand for effective therapies targeting the underlying mechanisms of NAFLD and NASH. These biologic treatments act on key metabolic and inflammatory pathways, offering a more targeted and disease-modifying approach compared with traditional lifestyle-based interventions that provide limited therapeutic impact for advanced disease. For instance, in March 2023, Akero Therapeutics, a US-based biotechnology company, reported positive Phase II reports of efruxifermin, indicated for the treatment of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). It is a differentiated Fc-FGF21 fusion protein that mimics the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes.

What Are Latest Mergers And Acquisitions In The Fatty Liver Treatment Market?

In March 2023, Ipsen, a France-based biopharmaceutical company, acquired Albireo Pharma Inc. for $952 million. The addition of Albireo significantly increased Ipsen's focus on rare illnesses with unique pipeline potential, promising therapies for uncommon cholestatic liver illnesses in children and adults, and scientific and commercial skills. The acquisition also expanded Ipsen's portfolio of rare diseases. Albireo Pharma Inc. is a US-based biotechnology company developing bile acid modulators that can be used to treat fatty liver disorders.

Regional Outlook

North America was the largest region in the fatty liver treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Fatty Liver Treatment Market?

The fatty liver treatment market consists of revenues earned by entities by providing medical evaluation, medical diagnosis, healthcare provider consultations, nutritional guidance, medication management, ongoing monitoring, and weight management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The fatty liver treatment market also includes sales of thiazolidinediones, vitamin E, metformin, statins, polyunsaturated fatty acids, angiotensin receptor blockers, and pentoxifylline, which are used in providing fatty liver treatment services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Fatty Liver Treatment Market Report 2026?

The fatty liver treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the fatty liver treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.